Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gynecological & Ovarian Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AMHR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AMHR2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View AMHR2 Products |
| Gene Delivery | AMHR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. |
View AMHR2 Products |
| Benchmark Ab | Anti-AMHR2 (Murlentamab & Pacmilimab Class) Recombinant positive control, sequence-verified CDRs. |
View AMHR2 Products |
| Validator | AMHR2 siRNA Set Three unique targets for knockdown verification. |
View AMHR2 Products |
| Ligand Control | AMH (Anti-Müllerian Hormone) Natural ligand for binding competition assays. |
View AMH Products |
| Related Target A | FOLR1 Synergistic solid tumor target for ovarian cancer bispecific/combination therapies. |
View FOLR1 Products |
| Related Target B | BMPR2 TGF-β superfamily receptor, off-target screening panel member. |
View BMPR2 Products |
| Related Target C | ACVR2B Activin receptor, structural homology control for selectivity testing. |
View ACVR2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cyno ortholog proteins available with >95% purity for SPR/BLI. Sequence Verified. |
| Internalization Assays for ADCs | HEK293-expressed ECD-Fc fusions preserving native conformation for pH-dependent binding and endocytosis tracking. |
| Cell-Based Signaling Assays | Lentivirus particles for stable HEK293 cell line generation; preserves full-length membrane topology for SMAD reporter assays. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies (Murlentamab & Pacmilimab biosimilars) included as positive controls. |
| False Positives in Cell Screening | Validated siRNA included for strict target-specificity knockdown checks; AMH ligand for competition binding. |
| Off-Target Selectivity | TGF-β superfamily selectivity panel (BMPR2, ACVR2B) available for cross-reactivity screening. |
Live AMHR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AMHR2 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to Antibody-Drug Conjugates (ADCs) and conditionally activated biologics. Originally validated by early clinical candidates like Murlentamab (GamaMabs Pharma) in advanced gynecological malignancies, and more recently by Pacmilimab (Bayer) in ovarian granulosa cell tumors, AMHR2 has emerged as an ideal target due to its highly restricted expression pattern—present on normal ovarian granulosa cells but overexpressed in ovarian, cervical, and endometrial carcinomas. As first-generation therapies establish safety profiles, the next wave of R&D is targeting AMHR2-driven ADCs to maximize intracellular payload delivery, leveraging the receptor's natural internalization mechanics. Combination strategies with PARP inhibitors and immune checkpoint blockade are also advancing in preclinical studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | GamaMabs Pharma (Murlentamab), Bayer (Pacmilimab) | Ovarian Cancer, Endometrial Cancer, Granulosa Cell Tumors | ADCC/ADCP Validation (Need high-purity HEK293 Antigens) |
| Antibody-Drug Conjugate (ADC) | Bayer, Emerging Biotechs | Refractory Solid Tumors, Ovarian Cancer | Internalization Assay (Need ECD-Fc for robust pH-dependent binding kinetics) |
| CAR-T / Bispecifics | Academic/Biotech Collaborations | Gynecological Malignancies, Immunotherapy combinations | T-Cell Activation (Need Lentivirus for target cell line construction) |
| Small Molecule | Early Discovery | Kinase domain inhibition | Mutant vs WT selectivity (Serine/Threonine kinase domain variants; e.g., PMDS mutations) |
Functional Domains & Key Mutations
AMHR2 (UniProt Q16671) is a serine/threonine protein kinase receptor belonging to the TGF-β superfamily. Its functional domains include:
- Protein kinase domain (residues 179–491): Catalytic activity critical for SMAD phosphorylation.
- Extracellular domain (residues 1–127): Ligand binding (AMH).
Key mutations associated with Persistent Müllerian Duct Syndrome (PMDS) include:
- PMDS2 mutation (rs534999427): Valine to Isoleucine substitution in the kinase domain.
- PMDS2 mutation (rs1352745784): Arginine to Glutamine substitution.
- PMDS2 mutation (rs539695176): Glycine to Arginine substitution. These mutations impair receptor signaling and are critical for studying rare genetic disorders.